- Sonnet BioTherapeutics Holdings Inc (NASDAQ:SONN) announced a collaboration agreement with Janssen Biotech Inc, a Johnson & Johnson (NYSE:JNJ) unit.
- In vitro and in vivo efficacy of SON-1010 (IL12-FHAB), SON-1210 (IL12-FHAB-IL15), and SON-1410 (IL18-FHAB-IL12) will be evaluated in combination with certain Janssen proprietary cell therapy assets.
- The agreement was facilitated by Johnson & Johnson Innovation.
- Sonnet shall supply the three referenced compounds for use in head-to-head studies. If successful and subject to provisions of the agreement, Sonnet could seek an expanded collaboration.
- “This is Sonnet’s first head-to-head evaluation of three FHAB-based drug candidates, the results of which will be instructive for expanded oncology indications. A successful evaluation could lead to a potential license agreement”, said Pankaj Mohan, Sonnet’s Founder and CEO.
- In September, Sonnet BioTherapeutics said that SB101 and SB102 studies dosed 19 subjects to date, with the early review of safety setting the stage for further dose escalation.
- Additional safety and cytokine-specific data are expected during the Q4 of 2022.
- Price Action: SONN shares are up 64.70% at $1.91 on the last check Monday.
Here’s How Much You Would Have Made Owning Madrigal Pharmaceuticals Stock In The Last 5 Years
Madrigal Pharmaceuticals (NASDAQ:MDGL) has outperformed the market over the past 5 years by 14.88% on an annualized basis…
